Alicia Morgans: Hi. My name is Alicia Morgans, and I am a GU Medical Oncologist and Associate Professor of Medicine at Northwestern University in Chicago. I’m so excited to have here with me today a good friend and colleague, Dr. Tian Zhang, who is an Associate Professor of Medicine at Duke in North Carolina. Thank […]
(UroToday.com) In the plenary program of the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Ana Aparicio discussed the potential for currently utilized treatments in advanced prostate cancer to drive a new resistant mutational phenotype within a session entitled “Beyond the Androgen Receptor: New Avengers in the Treatment of Castrate-Resistant Metastatic Cancer.”
(UroToday.com) Cisplatin and gemcitabine is a first line chemotherapy option for patients with metastatic urothelial carcinoma who are medically eligible to receive cisplatin. These chemotherapies induced DNA damage through distinct mechanisms, and it stands to reason that further disruption of DNA break repair may augment the efficacy of these agents. As the ATR (ataxia telangiectasia and […]
(UroToday.com) In the plenary program of the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Johann de Bono discussed emerging treatment options in advanced prostate cancer within a session entitled “Beyond the Androgen Receptor: New Avengers in the Treatment of Castrate-Resistant Metastatic Cancer.”
(UroToday.com) Following three presentations regarding various aspects of prostate cancer care with a focus on African American men in the Prostate, Testicular, and Penile Oral Abstract session at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Peter Black summarized these data and considered the question of whether we are improving the known racial disparities […]
(UroToday.com) In plenary program of the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Fleming discussed treatment sequencing in advanced prostate cancer within a session entitled “Beyond the Androgen Receptor: New Avengers in the Treatment of Castrate-Resistant Metastatic Cancer”.
The routine clinical implementation of molecular methods other than fluorescence in situ hybridization in the evaluation of renal neoplasia is currently limited, as the current standard of care primarily involves a combination of morphologic and immunophenotypic analysis of such tumors.
Background: Clear cell renal cell carcinoma (ccRCC) is a common malignant tumor of the urinary system. The ubiquitin proteasome system (UPS) plays an important role in the generation, metabolism and survival of tumor.
18F-Fluciclovine PET imaging has been increasingly used in the restaging of prostate cancer patients with biochemical recurrence (BCR); however, its clinical utility in patients with low prostate-specific antigen (PSA) levels following primary radiation therapy has not been well-studied.
Substantial geographic variation in healthcare practices exist. Active surveillance (AS) has emerged as a critical tool in the management of men with low-risk prostate cancer. Whether there have been regional differences in adoption is largely unknown.
